Follow-Up for Infections After Kidney Transplantation
Infection monitoring is a critical part of post-transplant care. During the first 3–6 months, the main goal is to prevent infections that take advantage of immunosuppression. After this early period, the focus shifts to managing long-term infectious risks associated with chronic immunosuppressive therapy.
- Viral Infection Monitoring
- BK Polyoma Virus (BKV):
Routine screening with quantitative plasma nucleic acid testing (NAT) should be performed monthly for the first 3–6 months, then every 3 months for the remainder of the first year.
Screening is also required whenever serum creatinine rises without explanation or after treatment for acute rejection.
If BKV levels exceed 10,000 copies/mL, reducing immunosuppression is recommended to prevent BKV nephropathy. - Cytomegalovirus (CMV):
At-risk recipients should receive chemoprophylaxis (usually valganciclovir) for 3 months post-transplant.
Patients receiving high immunosuppression for desensitization, or CMV-negative recipients with CMV-positive donors, should receive 6 weeks of prophylaxis after treatment.
If CMV disease develops, weekly monitoring is recommended until viral clearance. - Epstein–Barr Virus (EBV):
High-risk patients (Donor EBV-positive / Recipient EBV-negative) should be screened monthly for the first 6 months, then every 3 months until one year post-transplant.
A significant rise in EBV viral load should prompt a reduction in immunosuppression to prevent Post-Transplant Lymphoproliferative Disease (PTLD). - Other Viral Risks:
Patients should be monitored for Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV). Systemic infections require intravenous acyclovir and a reduction in immunosuppression.
Recipients with Hepatitis B (HBV) or Hepatitis C (HCV) should have monthly liver function tests for the first 6 months, then every 3–6 months thereafter.
- Bacterial and Fungal Prophylaxis
- Pneumocystis jirovecii (PCP) and UTIs:
All patients should receive co-trimoxazole (480 mg daily) for 3–6 months to prevent PCP and urinary tract infections.
Prophylaxis should be restarted for at least 6 weeks during and after treatment for acute rejection. - Tuberculosis (TB):
In selected high-risk patients, isoniazid prophylaxis (with pyridoxine) should be continued for 6 months.
If rifampin is used for treatment, CNI and mTOR inhibitor levels must be monitored closely due to drug interactions. - Candida:
Prophylaxis against oral and esophageal Candida (clotrimazole lozenges, nystatin, or fluconazole) is recommended for 1–3 months post-transplant and for 1 month after antilymphocyte antibody therapy.
- Vaccination and Blood Product Safety
- Inactivated Vaccines:
Annual influenza vaccination is recommended, starting at least one month after transplant.
Other inactivated vaccines are safe but ideally delayed until 3–6 months post-transplant when immunosuppression is lower. - Hepatitis B Surface Antibody (HBsAb):
Levels should be checked annually; revaccination is recommended if titers fall below 10 mIU/mL. - Live Vaccines:
Strictly contraindicated after transplantation due to the risk of causing infection in immunosuppressed patients. - Hepatitis E (HEV):
All patients should receive HEV-screened blood components to prevent persistent infection and potential progression to cirrhosis.
- Lifestyle and Environmental Precautions
Recipients should avoid foods with a high risk of contamination, such as raw shellfish and unpasteurized dairy products.
They should also be educated to report symptoms such as new skin lesions (which may be viral-driven) or signs of systemic inflammation.
